Published in final edited form as:

Curr Treat Options Gastroenterol. 2018 March ; 16(1): 15–26. doi:10.1007/s11938-018-0167-1.

New Developments in the Diagnosis, Therapy and Monitoring of Eosinophilic Esophagitis

Ronak Vashi Patel, MD and

Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL

Ikuo Hirano, MD

Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair, Suite 1400, Chicago, IL 60611

Abstract

Purpose of review—Eosinophilic esophagitis (EoE) has transformed over the past two decades from a little-known entity to a significant cause of morbidity in the adult and pediatric population. We reviewed the most recent advancements in the diagnosis, therapy, and long-term monitoring of EoE.

Recent findings—Based on clinical, endoscopic, histologic, immunologic and genetic similarities, there is growing consensus to move away from distinguishing proton pump inhibitor responsive esophageal eosinophilia as an entity distinct from EoE. An increasing number of studies have identified duration of untreated disease as an important determinant of esophageal stricture formation. New approaches to the empiric elimination diet including one, two, four, and step up protocols were developed to reduce the need for repeated endoscopies during reintroduction of food triggers. Topical steroids remain the mainstay of medical therapy but newer formulations are under development to optimize esophageal delivery. Novel, disease activity monitoring techniques are being evaluated that assess esophageal inflammatory activity without the need for endoscopy.

Summary—Understanding of EoE has increased remarkably from the first identification of the disease. The underlying pathogenesis continues to be explored leading to shifts in diagnostic criteria as well as novel therapeutic targets. Innovative methods to monitor disease are under investigation and more research is needed to understand the natural history of EoE.

Keywords

eosinophilic esophagitis; dysphagia; eosinophil; gastroesophageal reflux disease; esophagus

Correspondence to: Ikuo Hirano.

Compliance with Ethics Guidelines

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest

Ronak Vashi Patel declares no conflict of interest.

Ikuo Hirano has received consulting fees from Adare, Receptos, Regeneron, Allakos, and Shire.

Introduction

Eosinophilic esophagitis (EoE) is an immune-mediated disease characterized by increased esophageal mucosal eosinophils and esophageal dysfunction. The diagnosis of EoE is based upon clinical presentation paired with increased esophageal mucosal eosinophilia. Although previously considered a rare entity, the incidence and prevalence of EoE have dramatically increased over the past two decades, particularly in reports from the United States and Western Europe.[1] Over this same time period, a growing number of advances have increased our understanding of the clinical features, natural history, and medical/dietary therapy of EoE. This review summarizes recent studies in the field. (Figure 1)

Diagnosis

EoE is defined based on the combination of clinical symptoms and signs of esophageal dysfunction combined with esophageal mucosal biopsies demonstrating ≥ 15 eosinophils/high powered field (eos/hpf).[2] Current guidelines indicate that prior to making a diagnosis of EoE, other causes of esophageal eosinophilia be excluded, in particular, gastroesophageal reflux disease (GERD).[2–4] Differentiating between GERD and EoE can be challenging and phenotypic overlap exists.[5] Esophageal eosinophilia was first described as a histologic feature in GERD[6], but later identified in patients with dysphagia without reflux disease.[7] Researchers sought to identify independent predictors of EoE in distinction to GERD which included younger age, atopy, and endoscopic features such as rings, furrows, plaques, and exudates.[8, 9] As the entity of EoE evolved, guidelines incorporated the recommendation for a therapeutic trial of proton pump inhibitor (PPI) therapy for 6–8 weeks in an effort to distinguish distinct entities of GERD and EoE.[4] However, mounting evidence demonstrate that approximately 25–50% of patients with symptomatic, histologic, endoscopic, eosinophil-biomarker, and gene-expression features of EoE respond to PPI therapy calling into question the value of the PPI trial.[10] In 2011, guidelines acknowledged this growing uncertainty by incorporating the concept of “PPI-responsive esophageal eosinophilia” (PPI-REE).[3, 11] While most data on PPIREE has been in adult cohorts, a recent prospective study of children with esophageal eosinophilia (> 15 eos/hpf) also found no differences in atopy, allergy testing, pH testing, and endoscopic scores in patients with PPIREE compared to patients traditionally labeled as EoE.[12] Together, these recent studies support a paradigm shift to remove the criteria of failed PPI response prior to establishing a diagnosis of EoE and the inclusion of PPI-REE as true EoE.[13, 14] The diagnostic criteria for EoE still centers on typical clinical presentation including symptom presentation and endoscopic findings, which should minimize the risk of incorrect inclusion of GERD. Patients with a GERD phenotype (dominant heartburn, erosive esophagitis, abnormal pH testing) with esophageal eosinophilia would still be appropriate for a PPI trial prior to consideration of EoE specific therapy. Furthermore, given the high population prevalence of GERD, overlap between GERD and EoE is inevitable.

Natural History

EoE emerged as a rare disease in the 1990s [7] and now serves as a significant cause of GI morbidity. Annual costs in the United States related to EoE are estimated at nearly 1.4

billion dollars. [15] Previous studies have found EoE in over 10% of patients presenting with dysphagia.[16] With its growing recognition, the incidence of EoE has been estimated at a rate of 3.7/100,000 persons/year by one recent study.[17] The rise in disease patterns has been postulated to be related to environmental changes over the past decades and is supported by twin studies.[18]

Although EoE has a rising incidence and prevalence, the disease is still considered relatively new and long-term data are few. Nevertheless, increasing data support the chronicity of EoE with propensity for progressive esophageal remodeling resulting in stricture formation. In a prospective randomized, placebo-controlled, 50-week maintenance study of budesonide by Straumann et al., patients in the placebo group had an expected increase in esophageal eosinophilia but also recurrent dysphagia and an increase in subepithelial fibrosis.[19] This data supports retrospective studies that identified that longer duration of untreated EoE was associated with increased risk of esophageal strictures. Schoepfer et al. showed that strictures were seen in up to 39% of patients with a diagnostic delay of over 8 years and 70% with a delay of greater than 20 years.[20] New technology, known as the Functional Lumen Imaging Probe (FLIP), measures distensibility of the esophagus during volumetric distention. FLIP technology has been applied to the evaluation of the function and anatomy of the esophagus with a growing number of studies in EoE.[21–24] Recently, FLIP has been used in the pediatric population to highlight decreased distensibility in EoE patients. Those with higher eosinophil counts and lamina propria fibrosis had decreased distensibility leading to the concept that EoE can affect distensibility in children with EoE.[25] Carlson et al. identified that medical and dietary therapy significantly improved esophageal distensibility in 44% of adults with EoE, supporting the concept of reversibility of remodeling in EoE.[26]

Therapy

While diet, medications, and esophageal dilation remain effective therapies for EoE, recent advances are evaluating the efficacy of topical steroids optimized for esophageal delivery and biologic therapies targeting specific allergic pathways involved in the pathogenesis of EoE.

Diet

Elemental formula therapy for EoE was first described in the study by Kelly et al. in 1995 and remains the most effective diet therapy for EoE.[27] In spite of this, elemental diets have not been widely adopted due to poor patient compliance and palatability. Conceptually, given the antigen-mediated nature of EoE, allergy testing-directed elimination diets have been explored. However, studies to date have demonstrated a limited response to allergy directed therapy in adults with EoE.[28–30]

Empiric elimination diets targeting the most common food triggers related to EoE remain a more practical and effective option with 50–57% histologic response. The six-food elimination diet (SFED) that eliminates milk, egg, soy, wheat, peanuts/tree nuts, and fish/shellfish was first described in pediatric and subsequently adult EoE.[29, 31] Eliminating six major food categories can be difficult for patients and reintroduction can be challenging,

taking several months and requiring multiple endoscopies. Given the high presence of milk, soy/legumes, egg, and wheat to be identified as the food trigger for EoE patients[29, 32, 33], a four food elimination diet (FFED) has been reported.[34] In Molina-Infante et al.'s study of the FFED, about half of patients achieved clinical and histologic remission.[34] All patients only had one or two identified food triggers, most commonly milk. The patients who did not respond to the FFED were offered the SFED and one-third of these patients then achieved remission. Given the possibility of "step-up" therapy, a recent study by the same group utilized a novel "step up" approach eliminating milk and gluten first and then advancing to a FFED followed by SFED for non-responders (2-4-6 diet).[35] This incremental approach offered the advantage of reduced utilization of endoscopy during the reintroduction process.

The long-term effectiveness of diet therapy has been poorly studied. A prospective Spanish study reported a sustained histologic response for over 2 years but in only 15 adults.[32] A recent retrospective study of 52 adults treated with an elimination diet reported that about half of the patients who initially responded continued to maintain response with a mean follow up of 2 years.[36] In patients willing and able to continue avoidance of identified food trigger(s), diet elimination retained effectiveness. However, when factoring the reported lower than expected induction response of 40% (21/52), long-term histologic response to diet therapy was achieved in only 19% (10/52) of the cohort. Thus, the majority of patients either did not respond to diet or lost response over time due to diet non-adherence, indicating a considerable limitation to use of diet therapy for maintenance of EoE.

Corticosteroids

Swallowed, topical steroid therapy is the most commonly used therapeutic approach in EoE, providing direct effect to the mucosa and minimizing systemic side effects of systemic steroids. As no medication has been approved by US or European regulatory authorities for indication of EoE, topical steroids are being used off-label. Moreover, currently used formulations designed for asthma, especially using a metered dose inhaler, present challenges in terms of administration. Recent clinical trials have utilized steroid formulations optimized for esophageal delivery. A recent phase two randomized, double-blind, placebo controlled trial of budesonide oral suspension demonstrated significant improvement in dysphagia symptom scores, histologic findings, and endoscopic features. [37] Importantly, this study was the first to demonstrate improvement using validated patient reported outcome and endoscopic scoring instruments. In a European study, Miehke et al. studied 2 budesonide formulations in a randomized, double-blind trial.[38] Here, patients were randomized to treatment with a budesonide tablet, budesonide viscous suspension, or placebo. Histological remission and improvement in endoscopic scores was found in all budesonide groups as compared to placebo after 2 weeks of therapy.

Recent studies have raised concerns regarding the long-term effectiveness of topical steroids in adults with EoE. A retrospective study reported that 50% of adult patients with EoE had loss of response to steroids by 18.5 months and 75% by 29.6 months.[39] Similarly, a Swiss prospective study of budesonide demonstrated a loss of initial histologic response in 64% at 1 year follow up.[19] Most recently, a prospective, multi-center, open label study of

budesonide oral suspension found that 58% of initial histologic responders lost their response at 24 week follow-up.[40] All three studies attributed part of the loss of the steroid induction response to steroid dose reduction during maintenance phase, but more data is needed to clarify if steroid tolerance may develop in EoE.

Biologics

Addressing the allergic pathogenesis of EoE, several trials are evaluating the efficacy of novel biologic therapies targeting inflammatory cytokines. Interleukin-5 (IL-5), is involved in the activation and release of eosinophils from the bone marrow [41] and has been studied in hypereosinophilic syndromes and allergic asthma.[42] Mepolizumab, an anti-IL-5 immunoglobulin, was recently studied in pediatric EoE in a randomized trial by Assa'ad et al. Patients received one of three doses of mepolizumab every 4 weeks for three infusions. Peak eosinophil counts were less than 20/hpf in 32% of patients.[43] Another randomized controlled trial of mepolizumab in adult EoE supported these findings with reduction in mean eosinophil counts.[44] Interleukin 13 (IL-13) is an additional cytokine identified in higher expression in esophageal biopsies from patients with EoE.[45] Rothenberg et al. studied the use of anti-IL-13 therapy, QAX576, in patients with EoE.[46] Patients received QAX576 or placebo for 8 weeks. The primary endpoint of a decrease of 75% of peak eosinophil counts was not met, although mean counts did decrease by 60%. This improvement continued for six months after cessation of active therapy. [46] Another anti-IL-13 therapy, RPC4046, has also been shown to significantly decrease eosinophil counts and improve endoscopic features as compared to placebo.[47] Most recently, interleukin-4 (IL-4) has also been shown to have increased expression in patients with EoE.[48] A study of dupilumab, an antibody targeting signaling of both IL-4 and IL-13, is currently undergoing in patients with EoE. Preliminary reported data demonstrated improvement in dysphagia scores, endoscopic signs, and peak eosinophil counts with the use of dupilumab. [49] While many promising studies are searching for additional biologic targets, the long-term data on these agents are not known in EoE. It also remains unknown how biologic therapy will be positioned in patient management decisions. Postulated advantages of this form of therapy include avoidance of daily steroid administration, systemic effects that benefit multiple forms of allergic disease in highly atopic individuals, application for steroid refractory patients, and ability to improve esophageal remodeling.

Dilation

Dilation provides a direct approach to improve esophageal luminal diameter and decrease symptoms of dysphagia and risk of food impactions. As described earlier, progression of EoE and remodeling can lead to stricture formation.[20, 50] Food impaction and dysphagia are leading causes of morbidity in patients with EoE. Once fibrostenotic features have developed, it is unclear how effectively medical therapy can improve or reverse the process without dilation, although a recent study noted improved esophageal distensibility with medical therapy in the absence of esophageal dilation.[26]

Several studies have examined the safety and effectiveness of dilation therapy. A recent meta-analysis reviewed 845 EoE patients who underwent 1820 esophageal dilations.[51] Symptoms improved in over 95% of patients. Mean pre-dilation stricture measurements

were 9.9 mm and post-dilation measurements were 16 mm. Patients on average underwent 3 dilations, however, this number widely varied from 1 to 35 dilations per patient. Perforation, the most worrisome complication of dilation, was seen in 0.38% of patients (7/1831). Other major complications including hemorrhage (0.05%) and hospitalization (0.67%) were uncommon. This large scale meta-analysis highlights both the efficacy and safety of dilation therapy.[51] It should be noted that this data was almost exclusively based on retrospective studies from centers focusing on esophageal disorders. Estimates of complication rates need to acknowledge potential variation based on the experience in diverse practice settings. Ultimately, it would be the hope of all EoE therapy to halt the progression to fibrostenotic features and reduce the need for dilation.

Disease Monitoring

Primary disease therapeutic endpoints in EoE are grouped into clinical, histologic, and endoscopic outcomes that were recently reviewed in a conference sponsored by the American Gastroenterological Association with participation of the FDA and industry.[52] Historically, patient reported symptoms have not correlated well with disease activity such as esophageal eosinophil density.[53]. Scoring tools have been developed to assess patient symptoms and are currently used in clinical studies including the Dysphagia Symptom Questionnaire (DSQ) and EoE Activity Index (EEsAI). With novel endoscopic evaluation tools such as EREFS [54], features of EoE can now be more categorically represented. While a reproducible and objective outcome, there is considerable variability in what defines histologic response in terms of eosinophil density. The recent development of a more comprehensive histologic scoring tool (EoE-HSS) appears promising in terms of validation characteristics and ability to provide a more comprehensive assessment of a broader range of pathologic features in EoE.[55]

Esophagogastroduodenoscopy (EGD) is an important modality for diagnosis and monitoring of disease. Given that many patients present with dysphagia, EGD is needed to obtain biopsies as well as rule out diagnoses aside from EoE. While is often required in the initial work up of patients, guidelines do not specify the interval at which to perform follow up endoscopic evaluation. The timing of repeat EGD is generally determined on a case by case basis, although commonly performed 2–3 months following a therapeutic intervention. Although a primary monitoring method, EGD carries high costs and remains an invasive procedure requiring sedation.

Newer, less invasive technologies are being developed to assess disease activity. In 2012, researchers studied the use of an esophageal string test to measure eosinophil-derived proteins in luminal secretions. Protein levels correlated with eosinophil counts and could distinguish between active EoE, GERD, and normal controls.[56] A study by Kern et al. highlighted the ability of cytologic brushings to be used.[57] Compared to esophageal biopsy, the sensitivity and specificity of brushings was estimated at around 70% both proximally and distally. The concept of collecting superficial cells has also previously been studied in Barrett's esophagus.[58] Similarly, in EoE, the Cytosponge device (Medtronic) has been investigated. The Cytosponge is a device contained within a dissolving capsule. Patients swallow the capsule which then expands into a small mesh sponge after the outer

gelatin shell dissolves. The sponge is connected to a string and then withdrawn from the oral cavity as it samples esophageal cells. Studies using the cytosponge in EoE patients have shown a sensitivity of 83% and a specificity of 57%. [59] A more recent study showed a slightly lower sensitivity of 75% and a higher specificity of 86% of the Cytosponge device. [60] Both studies used the same cutoff of 15 eosinophils/hpf for disease activity, but the latter examined nearly five times the number of paired samples. Though all three of these new technologies are less invasive, structural changes of EoE are not assessed.

Transnasal endoscopy (TNE) has been developed and now studied in EoE as an alternative to traditional endoscopy. TNE does not require sedation and can be done in the outpatient clinic. TNE has previously been compared to EGD and shown to be a safe technique. [61] In the pediatric EoE population, TNE has been used for monitoring and obtaining esophageal specimens for eosinophilic analysis. [62] Parents in this study largely preferred TNE to EGD.

As mentioned previously, FLIP technology has now been used to investigate distensibility characteristics of patients with EoE. Higher severity of rings according to the EREFS score correlated with lower distensibility measures of remodeling by FLIP. [63] The FLIP catheter is passed through the oropharynx for measurements during routine endoscopy. Specialty centers are currently evaluating this technology as an adjunct to traditional endoscopy. [24]

Conclusion

Knowledge regarding EoE has grown markedly over the past two decades. Initially a disease seldom encountered, EoE is now widely recognized as a common cause of esophageal symptoms in children and adults. Much has been learned about EoE and its distinction and overlap with an even more common disorder, GERD. Studies have highlighted the chronicity of disease and progression to fibrostenosis. With the understanding of EoE as an immune-mediated disease, therapies are targeted to eliminating antigen exposure through diet and decreasing the inflammatory response with steroids and biologic therapies. The long-term management of EoE is evolving. Patients and physicians both realize the cumbersome nature of repeated EGDs and newer, less invasive technologies are being studied. EoE remains an evolving entity and more is yet to be discovered about this young disease.

References

1. Dellon ES, Hirano I. Epidemiology and Natural History of Eosinophilic Esophagitis. *Gastroenterology*. 2017; doi: 10.1053/j.gastro.2017.06.067
2. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). *Am J Gastroenterol*. 2013; 108(5):679–92. quiz 93. DOI: 10.1038/ajg.2013.71 [PubMed: 23567357]
3. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. *J Allergy Clin Immunol*. 2011; 128(1):3–20. e6. quiz 1–2. DOI: 10.1016/j.jaci.2011.02.040 [PubMed: 21477849]
4. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. *Gastroenterology*. 2007; 133(4):1342–63. DOI: 10.1053/j.gastro.2007.08.017 [PubMed: 17919504]

5. Kia L, Hirano I. Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies. *Nat Rev Gastroenterol Hepatol*. 2015; 12(7):379–86. DOI: 10.1038/nrgastro.2015.75 [PubMed: 25986303]
6. Winter HS, Madara JL, Stafford RJ, Grand RJ, Quinlan JE, Goldman H. Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis. *Gastroenterology*. 1982; 83(4):818–23. [PubMed: 7106512]
7. Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. *Dig Dis Sci*. 1993; 38(1):109–16. [PubMed: 8420741]
8. Dellon ES, Gibbs WB, Fritchie KJ, Rubinas TC, Wilson LA, Woosley JT, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. *Clin Gastroenterol Hepatol*. 2009; 7(12):1305–13. quiz 261. DOI: 10.1016/j.cgh.2009.08.030 [PubMed: 19733260]
9. Hirano I. Eosinophilic esophagitis and gastroesophageal reflux disease: there and back again. *Clin Gastroenterol Hepatol*. 2011; 9(2):99–101. DOI: 10.1016/j.cgh.2010.11.001 [PubMed: 21070874]
10. Molina-Infante J, Ferrando-Lamana L, Ripoll C, Hernandez-Alonso M, Mateos JM, Fernandez-Bermejo M, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. *Clin Gastroenterol Hepatol*. 2011; 9(2):110–7. DOI: 10.1016/j.cgh.2010.09.019 [PubMed: 20920599]
11. Ngo P, Furuta GT, Antonioli DA, Fox VL. Eosinophils in the esophagus--peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. *Am J Gastroenterol*. 2006; 101(7):1666–70. DOI: 10.1111/j.1572-0241.2006.00562.x [PubMed: 16863575]
12. Gutierrez-Junquera C, Fernandez-Fernandez S, Cilleruelo ML, Rayo A, Echeverria L, Quevedo S, et al. High Prevalence of Response to Proton-pump Inhibitor Treatment in Children With Esophageal Eosinophilia. *J Pediatr Gastroenterol Nutr*. 2016; 62(5):704–10. DOI: 10.1097/MPG.0000000000001019 [PubMed: 26513622]
13. Molina-Infante J, Gonzalez-Cordero PL, Lucendo AJ. Proton pump inhibitor-responsive esophageal eosinophilia: still a valid diagnosis? *Curr Opin Gastroenterol*. 2017; 33(4):285–92. DOI: 10.1097/MOG.0000000000000371 [PubMed: 28445189]
14. Moawad FJ, Schoepfer AM, Safroneeva E, Ally MR, Chen YJ, Maydonovitch CL, et al. Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings. *Aliment Pharmacol Ther*. 2014; 39(6):603–8. DOI: 10.1111/apt.12636 [PubMed: 24461332]
15. Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. *Am J Gastroenterol*. 2015; 110(5):626–32. DOI: 10.1038/ajg.2014.316 [PubMed: 25267327]
16. Mackenzie SH, Go M, Chadwick B, Thomas K, Fang J, Kuwada S, et al. Eosinophilic oesophagitis in patients presenting with dysphagia--a prospective analysis. *Aliment Pharmacol Ther*. 2008; 28(9):1140–6. DOI: 10.1111/j.1365-2036.2008.03795.x [PubMed: 18624788]
17. Arias A, Perez-Martinez I, Tenias JM, Lucendo AJ. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. *Aliment Pharmacol Ther*. 2016; 43(1):3–15. DOI: 10.1111/apt.13441
18. Alexander ES, Martin LJ, Collins MH, Kottyan LC, Sucharew H, He H, et al. Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis. *J Allergy Clin Immunol*. 2014; 134(5):1084–92. e1. DOI: 10.1016/j.jaci.2014.07.021 [PubMed: 25258143]
19. Straumann A, Conus S, Degen L, Frei C, Bussmann C, Beglinger C, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. *Clin Gastroenterol Hepatol*. 2011; 9(5):400–9. e1. DOI: 10.1016/j.cgh.2011.01.017 [PubMed: 21277394]
20. Schoepfer AM, Safroneeva E, Bussmann C, Kuchen T, Portmann S, Simon HU, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. *Gastroenterology*. 2013; 145(6):1230–6. e1–2. DOI: 10.1053/j.gastro.2013.08.015 [PubMed: 23954315]

21. Lin Z, Kahrilas PJ, Xiao Y, Nicodeme F, Gonsalves N, Hirano I, et al. Functional luminal imaging probe topography: an improved method for characterizing esophageal distensibility in eosinophilic esophagitis. *Therap Adv Gastroenterol*. 2013; 6(2):97–107. DOI: 10.1177/1756283X12470017
22. McMahon BP, Frokjaer JB, Kunwald P, Liao D, Funch-Jensen P, Drewes AM, et al. The functional lumen imaging probe (FLIP) for evaluation of the esophagogastric junction. *Am J Physiol Gastrointest Liver Physiol*. 2007; 292(1):G377–84. DOI: 10.1152/ajpgi.00311.2006 [PubMed: 16950760]
23. Carlson DA, Lin Z, Hirano I, Gonsalves N, Zalewski A, Pandolfino JE. Evaluation of esophageal distensibility in eosinophilic esophagitis: an update and comparison of functional lumen imaging probe analytic methods. *Neurogastroenterol Motil*. 2016; 28(12):1844–53. DOI: 10.1111/nmo.12888 [PubMed: 27311807]
24. Hirano I, Pandolfino JE, Boeckxstaens GE. Functional Lumen Imaging Probe for the Management of Esophageal Disorders: Expert Review From the Clinical Practice Updates Committee of the AGA Institute. *Clin Gastroenterol Hepatol*. 2017; 15(3):325–34. DOI: 10.1016/j.cgh.2016.10.022 [PubMed: 28212976]
25. Menard-Katcher C, Benitez AJ, Pan Z, Ahmed FN, Wilkins BJ, Capocelli KE, et al. Influence of Age and Eosinophilic Esophagitis on Esophageal Distensibility in a Pediatric Cohort. *Am J Gastroenterol*. 2017; 112(9):1466–73. DOI: 10.1038/ajg.2017.131 [PubMed: 28508868]
26. Carlson DA, Hirano I, Zalewski A, Gonsalves N, Lin Z, Pandolfino JE. Improvement in Esophageal Distensibility in Response to Medical and Diet Therapy in Eosinophilic Esophagitis. *Clin Transl Gastroenterol*. 2017; 8(10):e119. • First study to demonstrate significant improvement in esophageal distensibility following medical therapy in the absence of esophageal dilation in patients with eosinophilic esophagitis using the functional lumen imaging probe (FLIP). doi: 10.1038/ctg.2017.47 [PubMed: 28981080]
27. Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. *Gastroenterology*. 1995; 109(5):1503–12. [PubMed: 7557132]
28. Molina-Infante J, Martin-Noguerol E, Alvarado-Arenas M, Porcel-Carreno SL, Jimenez-Timon S, Hernandez-Arbeiza FJ. Selective elimination diet based on skin testing has suboptimal efficacy for adult eosinophilic esophagitis. *J Allergy Clin Immunol*. 2012; 130(5):1200–2. DOI: 10.1016/j.jaci.2012.06.027 [PubMed: 22867695]
29. Gonsalves N, Yang GY, Doerfler B, Ritz S, Ditto AM, Hirano I. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. *Gastroenterology*. 2012; 142(7):1451–9. e1. quiz e14–5. DOI: 10.1053/j.gastro.2012.03.001 [PubMed: 22391333]
30. Paquet B, Begin P, Paradis L, Drouin E, Des Roches A. Variable yield of allergy patch testing in children with eosinophilic esophagitis. *J Allergy Clin Immunol*. 2013; 131(2):613. doi: 10.1016/j.jaci.2012.10.053
31. Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. *Clin Gastroenterol Hepatol*. 2006; 4(9):1097–102. DOI: 10.1016/j.cgh.2006.05.026 [PubMed: 16860614]
32. Lucendo AJ, Arias A, Gonzalez-Cervera J, Yague-Compadre JL, Guagnozzi D, Angueira T, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. *J Allergy Clin Immunol*. 2013; 131(3):797–804. DOI: 10.1016/j.jaci.2012.12.664 [PubMed: 23375693]
33. Kagalwalla AF, Shah A, Li BU, Sentongo TA, Ritz S, Manuel-Rubio M, et al. Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. *J Pediatr Gastroenterol Nutr*. 2011; 53(2):145–9. DOI: 10.1097/MPG.0b013e31821cf503 [PubMed: 21788754]
34. Molina-Infante J, Arias A, Barrio J, Rodriguez-Sanchez J, Sanchez-Cazalilla M, Lucendo AJ. Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study. *J Allergy Clin Immunol*. 2014; 134(5):1093–9. e1. DOI: 10.1016/j.jaci.2014.07.023 [PubMed: 25174868]

35. Molina-Infante J, Gonzalez-Cordero PL, Arias A, Lucendo AJ. Update on dietary therapy for eosinophilic esophagitis in children and adults. *Expert Rev Gastroenterol Hepatol*. 2017; 11(2): 115–23. DOI: 10.1080/17474124.2017.1271324 [PubMed: 27998193]
36. Reed CC, Fan C, Koutlas NT, Shaheen NJ, Dellon ES. Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis. *Aliment Pharmacol Ther*. 2017; doi: 10.1111/apt.14290
37. Dellon ES, Katzka DA, Collins MH, Hamdani M, Gupta SK, Hirano I, et al. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. *Gastroenterology*. 2017; 152(4):776–86. e5. • First randomized, placebo controlled trial to demonstrate efficacy of medical therapy for eosinophilic esophagitis (liquid suspension of budesonide optimized for esophageal delivery) using a validated patient reported outcome instrument. DOI: 10.1053/j.gastro.2016.11.021 [PubMed: 27889574]
38. Miehke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M, et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. *Gut*. 2016; 65(3):390–9. • Randomized, placebo controlled trial demonstrating histologic efficacy of liquid and tablet formulations of budesonide optimized for esophageal delivery. DOI: 10.1136/gutjnl-2014-308815 [PubMed: 25792708]
39. Eluri S, Runge TM, Hansen J, Kochar B, Reed CC, Robey BS, et al. Diminishing Effectiveness of Long-Term Maintenance Topical Steroid Therapy in PPI Non-Responsive Eosinophilic Esophagitis. *Clin Transl Gastroenterol*. 2017; 8(6):e97.doi: 10.1038/ctg.2017.27 [PubMed: 28617448]
40. Dellon ES, Katzka D, Collins MH, Hamdani M, Gupta S, Hirano I. Safety and Efficacy of Oral Budesonide Suspension for Maintenance Therapy in Eosinophilic Esophagitis: Results From a Prospective Open-Label Study of Adolescents and Adults. *Gastroenterology*. 2016; 150(4):S188. • Prospective study of maintenance therapy for eosinophilic esophagitis demonstrating safety as well as diminished long-term effectiveness of topical budesonide following dose-reduction.
41. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GM-CSF. *Blood*. 1989; 73(6):1504–12. [PubMed: 2653458]
42. Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. *J Allergy Clin Immunol*. 2004; 113(1):115–9. DOI: 10.1016/j.jaci.2003.10.049 [PubMed: 14699394]
43. Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. *Gastroenterology*. 2011; 141(5):1593–604. DOI: 10.1053/j.gastro.2011.07.044 [PubMed: 21835135]
44. Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. *Gut*. 2010; 59(1):21–30. DOI: 10.1136/gut.2009.178558 [PubMed: 19828470]
45. Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. *J Allergy Clin Immunol*. 2007; 120(6):1292–300. DOI: 10.1016/j.jaci.2007.10.024 [PubMed: 18073124]
46. Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. *J Allergy Clin Immunol*. 2015; 135(2):500–7. DOI: 10.1016/j.jaci.2014.07.049 [PubMed: 25226850]
47. Hirano I, Collins MH, Assouline-Dayana Y, Evans L, Gupta S, Schopfer A, et al. A randomised, double-blind, placebo-controlled trial of a novel recombinant, humanised, anti-interleukin-13 monoclonal antibody (RPC4046) in patients with active eosinophilic oesophagitis: results of the heroes study. *United European Gastroenterology Journal*. 2016; 2(Supplement 1)
48. Blanchard C, Stucke EM, Rodriguez-Jimenez B, Burwinkel K, Collins MH, Ahrens A, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. *J Allergy Clin Immunol*. 2011; 127(1):208–17. 17 e1–7. DOI: 10.1016/j.jaci.2010.10.039 [PubMed: 21211656]

49. Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Dupilumab Efficacy and Safety in Adult Patients With Active Eosinophilic Esophagitis: A Randomized Double-Blind Placebo-Controlled Phase 2 Trial. American College of Gastroenterology Annual Scientific Meeting. 2017
50. Dellon ES, Kim HP, Sperry SL, Rybnicek DA, Woosley JT, Shaheen NJ. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. *Gastrointest Endosc.* 2014; 79(4):577–85. e4. DOI: 10.1016/j.gie.2013.10.027 [PubMed: 24275329]
51. Moawad FJ, Molina-Infante J, Lucendo AJ, Cantrell SE, Tmanova L, Douglas KM. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. *Aliment Pharmacol Ther.* 2017; 46(2):96–105. DOI: 10.1111/apt.14123 [PubMed: 28513085]
52. Hirano I, Spechler S, Furuta G, Dellon ES. White Paper AGA: Drug Development for Eosinophilic Esophagitis. *Clin Gastroenterol Hepatol.* 2017; 15(8):1173–83. • Summary of a drug development conference sponsored by the American Gastroenterological Association with participation of representatives from the FDA and pharmaceutical industry that focused on issues regarding trial design and therapeutic endpoints. DOI: 10.1016/j.cgh.2017.03.016 [PubMed: 28342955]
53. Safroneeva E, Straumann A, Coslovsky M, Zwahlen M, Kuehni CE, Panczak R, et al. Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. *Gastroenterology.* 2016; 150(3):581–90. e4. DOI: 10.1053/j.gastro.2015.11.004 [PubMed: 26584601]
54. Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. *Gut.* 2013; 62(4):489–95. DOI: 10.1136/gutjnl-2011-301817 [PubMed: 22619364]
55. Collins MH, Martin LJ, Alexander ES, Boyd JT, Sheridan R, He H, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. *Dis Esophagus.* 2017; 30(3):1–8. • This article presents a novel, comprehensive histology scoring system as compared to traditional peak eosinophil count measurements for the assessment of EoE activity. DOI: 10.1111/dote.12470
56. Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. *Gut.* 2013; 62(10):1395–405. DOI: 10.1136/gutjnl-2012-303171 [PubMed: 22895393]
57. Kern E, Lin D, Larson A, Yang GY, Taft T, Zalewski A, et al. Prospective assessment of the diagnostic utility of esophageal brushings in adults with eosinophilic esophagitis. *Dis Esophagus.* 2016; 29(1):48–53. DOI: 10.1111/dote.12304 [PubMed: 25515533]
58. Benaglia T, Sharples LD, Fitzgerald RC, Lyrtzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. *Gastroenterology.* 2013; 144(1):62–73. e6. DOI: 10.1053/j.gastro.2012.09.060 [PubMed: 23041329]
59. Katzka DA, Geno DM, Ravi A, Smyrk TC, Lao-Sirieix P, Miremadi A, et al. Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis. *Clin Gastroenterol Hepatol.* 2015; 13(1):77–83. e2. DOI: 10.1016/j.cgh.2014.06.026 [PubMed: 24997328]
60. Katzka DA, Smyrk TC, Alexander JA, Geno DM, Beitia RA, Chang AO, et al. Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study. *Am J Gastroenterol.* 2017; •• Prospective study supporting the accuracy of the Cytosponge for assessing inflammatory activity of eosinophilic esophagitis. doi: 10.1038/ajg.2017.244
61. Yagi J, Adachi K, Arima N, Tanaka S, Ose T, Azumi T, et al. A prospective randomized comparative study on the safety and tolerability of transnasal esophagogastroduodenoscopy. *Endoscopy.* 2005; 37(12):1226–31. DOI: 10.1055/s-2005-921037 [PubMed: 16329022]
62. Friedlander JA, DeBoer EM, Soden JS, Furuta GT, Menard-Katcher CD, Atkins D, et al. Unsedated transnasal esophagoscopy for monitoring therapy in pediatric eosinophilic esophagitis. *Gastrointest Endosc.* 2016; 83(2):299–306. e1. DOI: 10.1016/j.gie.2015.05.044 [PubMed: 26142551]

63. Chen JW, Pandolfino JE, Lin Z, Ciolino JD, Gonsalves N, Kahrilas PJ, et al. Severity of endoscopically identified esophageal rings correlates with reduced esophageal distensibility in eosinophilic esophagitis. *Endoscopy*. 2016; 48(9):794–801. DOI: 10.1055/s-0042-107340 [PubMed: 27200524]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

Summary of recent developments in EoE. PPI-REE: proton pump inhibitor responsive esophageal eosinophilia; EoE: eosinophilic esophagitis